88.2
Boris Kovatchev
University of Virginia
Boris Kovatchev's research has significantly advanced the field of type 1 diabetes management. Their work focuses on developing adaptive bio-behavioral control systems, novel detection markers, and artificial intelligence-based decision support tools to improve glycemic control. Recent studies have investigated the safety and efficacy of automated insulin delivery in adults at high risk for hypoglycemia, highlighting its potential benefits over traditional therapies. Kovatchev's research has also shed light on biobehavioral changes following transition to automated insulin delivery, menstrual cycle-related glucose variability, and essential continuous glucose monitoring metrics. By integrating machine learning and clinical insights, Kovatchev's work aims to enhance the quality of life for individuals with type 1 diabetes.
Firms applying this knowledge
Dexcom, Inc., University Of Virginia Patent Foundation, Abbott Diabetes Care, Inc., Roche Diabetes Care, Inc., Arizona Board Of Regents On Behalf Of Arizona State University, Insuline Medical Ltd., Animas Corporation, Glysens Incorporated, The Regents Of The University Of California, Acalvio Technologies, Inc., Vtv Therapeutics Llc, Shadow Networks, Inc., Bigfoot Biomedical, Inc., Dreamed Diabetes Ltd., Vanderbilt University, Autonomous Healthcare, Inc., Novo Nordisk A/S, Fitscript Llc, Roche Diagnostics Operations, Inc., University Of Newcastle Upon Tyne, Medtronic Minimed, Inc., Abbot Diabetes Care Inc., The University Of Toledo, The United States Of America As Represented By The Secretary, Department Of Health And Human Services